Related Experiment Video
Updated: Jun 24, 2026
07:17
Remotely Triggered LAD Occlusion Using a Balloon Catheter in Spontaneously Breathing Mice
Published on: March 22, 2024
Ranolazine as an adjunct to cardioplegia: a potential new therapeutic application
Hyosook Hwang1, Joseph M Arcidi, Sharon L Hale
1Heart Institute, Good Samaritan Hospital, Los Angeles, California 90017, USA.
Journal of Cardiovascular Pharmacology and Therapeutics
|March 31, 2009
Summary
Ranolazine enhances cardioplegia protection during cardiac arrest. This antianginal drug addition improved heart function and reduced damage from ischemia and reperfusion.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Hyperkalemic cardioplegia is a standard method to protect the heart during surgery.
- Ischemia and reperfusion can lead to cardiac contracture and elevated left ventricular end-diastolic pressure (LVEDP).
Purpose of the Study:
- To investigate the therapeutic potential of ranolazine as an adjunct to hyperkalemic cardioplegia.
- To assess ranolazine's effect on preventing cardiac contracture and LVEDP elevation during ischemia-reperfusion.
Main Methods:
- Rat hearts were Langendorff-perfused and subjected to 40 minutes of ischemia followed by 30 minutes of reperfusion.
- Experimental groups included control (no treatment), cardioplegia alone, and cardioplegia with 50 micromol/L ranolazine.
- Key measurements included time to contracture and LVEDP during reperfusion.
Main Results:
- Cardioplegia significantly prolonged the time to contracture compared to control (25 +/- 2 min vs. 12 +/- 1 min).
- Ranolazine further extended the time to contracture (34 +/- 2 min) and significantly reduced LVEDP elevation during reperfusion (17 +/- 2 mm Hg vs. 32 +/- 3 mm Hg with cardioplegia alone).
Conclusions:
- Ranolazine acts as a beneficial adjunctive therapy to hyperkalemic cardioplegia.
- The addition of ranolazine provides enhanced protection against cardiac contracture and ischemia-reperfusion injury.
Related Concept Videos
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
01:25Cardiopulmonary Resuscitation IV: Pharmacological Management
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
01:26Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
01:20Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...